Zobrazeno 1 - 10
of 578
pro vyhledávání: '"EBOV"'
Autor:
Ha-Na Lee, Biying Xu, Aaron P. Lewkowicz, Kaliroi Engel, Logan Kelley-Baker, Ian L. McWilliams, Derek D.C. Ireland, Jennifer L. Kielczewski, Jinbo Li, Robert N. Fariss, Mercedes M. Campos, Alina Baum, Christos Kyratsous, Kristen Pascal, Chi-Chao Chan, Rachel R. Caspi, Mohanraj Manangeeswaran, Daniela Verthelyi
Publikováno v:
EBioMedicine, Vol 104, Iss , Pp 105170- (2024)
Summary: Background: Ebola virus disease (EVD) survivors experience ocular sequelae including retinal lesions, cataracts, and vision loss. While monoclonal antibodies targeting the Ebola virus glycoprotein (EBOV-GP) have shown promise in improving pr
Externí odkaz:
https://doaj.org/article/22fa242296984e11a7988fdc6dae6cdd
Autor:
Eve Richardson, Sagida Bibi, Florence McLean, Lisa Schimanski, Pramila Rijal, Marie Ghraichy, Valentin von Niederhäusern, Johannes Trück, Elizabeth A. Clutterbuck, Daniel O’Connor, Kerstin Luhn, Alain Townsend, Bjoern Peters, Andrew J. Pollard, Charlotte M. Deane, Dominic F. Kelly
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Outbreaks of Ebolaviruses, such as Sudanvirus (SUDV) in Uganda in 2022, demonstrate that species other than the Zaire ebolavirus (EBOV), which is currently the sole virus represented in current licensed vaccines, remain a major threat to global healt
Externí odkaz:
https://doaj.org/article/245451aecafd4d5884059c3f71712a1a
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 1, Pp 21-55 (2024)
Abstract In 1976 Ebola revealed itself to the world, marking the beginning of a series of localized outbreaks. However, it was the Ebola outbreak that began in 2013 that incited fear and anxiety around the globe. Since then, our comprehension of the
Externí odkaz:
https://doaj.org/article/cfe53cc1ea874fc8867a85ee442f51f6
Autor:
Dylan M. Johnson, Terry Juelich, Lihong Zhang, Jennifer K. Smith, Birte K. Kalveram, David Perez, Jeanon Smith, Michael R. Grimes, Tania Garron, Maricela Torres, Shane Massey, Trevor Brasel, David W. C. Beasley, Alex N. Freiberg, Jason E. Comer
Publikováno v:
Viruses, Vol 16, Iss 7, p 1101 (2024)
Favipiravir is a ribonucleoside analogue that has been explored as a therapeutic for the treatment of Ebola Virus Disease (EVD). Promising data from rodent models has informed nonhuman primate trials, as well as evaluation in patients during the 2013
Externí odkaz:
https://doaj.org/article/930a651013754a5698d362b0dbc18049
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Daniel Mukadi-Bamuleka, Junior Bulabula-Penge, Bart K.M. Jacobs, Anja De Weggheleire, François Edidi-Atani, Fabrice Mambu-Mbika, Anaïs Legand, John D. Klena, Peter N. Fonjungo, Placide Mbala-Kingebeni, Sheila Makiala-Mandanda, Masahiro Kajihara, Ayato Takada, Joel M. Montgomery, Pierre Formenty, Jean-Jacques Muyembe-Tamfum, Kevin K. Ariën, Johan van Griensven, Steve Ahuka-Mundeke, Hgo Kavunga-Membo, Elie Ishara-Nshombo, Stijn Roge, Noella Mulopo-Mukanya, Espérance Tsiwedi-Tsilabia, Emile Muhindo-Milonde, Marie-Anne Kavira-Muhindo, Maria E. Morales-Betoulle, Antoine Nkuba-Ndaye
Publikováno v:
EBioMedicine, Vol 91, Iss , Pp 104568- (2023)
Summary: Background: Ebola virus disease (EVD) outbreaks have emerged in Central and West Africa. EVD diagnosis relies principally on RT-PCR testing with GeneXpert®, which has logistical and cost restrictions at the peripheral level of the health sy
Externí odkaz:
https://doaj.org/article/cf5c87b26a334407980ae4e8ff672710
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/f8d8330cfc3a4b49a8413836f1abc8a0
Autor:
Junqi Zhang, Baozeng Sun, Wenyang Shen, Zhenjie Wang, Yang Liu, Yubo Sun, Jiaxing Zhang, Ruibo Liu, Yongkai Wang, Tianyuan Bai, Zilu Ma, Cheng Luo, Xupeng Qiao, Xiyang Zhang, Shuya Yang, Yuanjie Sun, Dongbo Jiang, Kun Yang
Publikováno v:
Vaccines, Vol 11, Iss 10, p 1620 (2023)
(1) Background and Purpose: Ebola virus (EBOV) is the causative agent of Ebola virus disease (EVD), which causes extremely high mortality and widespread epidemics. The only glycoprotein (GP) on the surface of EBOV particles is the key to mediating vi
Externí odkaz:
https://doaj.org/article/0b60db9d70c644ce8974a0976212b490
Autor:
Ha-Na Lee, Ian L. McWilliams, Aaron P. Lewkowicz, Kaliroi Engel, Derek D. C. Ireland, Logan Kelley-Baker, Seth Thacker, Pedro Piccardo, Mohanraj Manangeeswaran, Daniela Verthelyi
Publikováno v:
Emerging Microbes and Infections, Vol 10, Iss 1, Pp 2076-2089 (2021)
Ebola virus (EBOV) infections cause haemorrhagic fever, multi-organ failure and death, and survivors can experience neurological sequelae. Licensing of monoclonal antibodies targeting EBOV glycoprotein (EBOV-GP) improved its prognosis, however, this
Externí odkaz:
https://doaj.org/article/d872a120c2254056bd329b2d88e1c4f7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.